Preclinical In-vivo Imaging Market

Preclinical In-vivo Imaging Market Size (2023 to 2028)

The size of the global preclinical in-vivo imaging market is forecasted to grow at a CAGR of 5.76% from 2023 to 2028. The size of the market is predicted to value USD 1056.9 million by 2028 from USD 798.8 million in 2023.

Preclinical imaging is the visualization of living animals for research purposes, such as drug development. Imaging modalities are crucial for researchers to observe changes, either at the organ, tissue, cell, or molecular level, responding to physiological or environmental changes. Non-invasive imaging modalities and in-vivo are essential to study animal models longitudinally. Techniques such as high-frequency micro-ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) are usually used for anatomical imaging. In contrast, optical imaging (fluorescence and bioluminescence), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) are usually used for molecular visualizations. The preclinical in-vivo imaging industry has experienced myriad technological advancements, market changes due to industry consolidation, and growth in government funding and support for research studies across the globe over the past decade.

Globally, factors such as technological advancements in molecular imaging modalities and the growing acceptance of preclinical imaging as a legitimate drug development tool are fuelling the demand for preclinical imaging systems and reagents.

Declining NIH budgets for medical science research studies and the high implementation cost of sophisticated preclinical imaging systems restrict the growth of the global preclinical imaging market.

REPORT COVERAGE:

This research report on the global preclinical in-vivo imaging market has been segmented and sub-segmented based on the modality, reagent, and region.

Preclinical In-vivo Imaging Market - By Modality:                

• Optical imaging      
  • Bioluminescence/fluorescence imaging systems
  • Standalone fluorescence imaging systems
  • Optical + X-ray/optical + CT imaging systems
• Nuclear imaging    
  • Micro-PET systems (standalone PET, PET/CT, and PET/MRI)
  • Micro-SPECT systems (standalone SPECT, SPECT/CT, and SPECT/MRI)
  • Tri-modality (PET/SPECT/CT) imaging systems
• Micro-MRI               
• Micro-CT  
• Micro-ultrasound 
• Photoacoustic        
• Magnetic particle imaging systems         

Based on modality, the segment of Micro-ultrasound is anticipated to grow with the fastest CAGR. It would be a significant contributor to the global market for preclinical In-vivo imaging. Micro-ultrasound is a smaller ultrasound version with a wider variety of applications, particularly in small animal model research. Some smaller versions of imaging methods improve the techniques ' efficacy. These often decrease the number of animals required for a specific study.      

Preclinical In-vivo Imaging Market - By Reagent:             

• Optical imaging reagents   
  • Bioluminescent reagents
  • Fluorescent imaging reagents
• Nuclear imaging reagents 
  • Preclinical PET tracers
  • Preclinical SPECT probes
• MRI contrast agents            
• Ultrasound contrast agents             
• CT contrast agents              

Based on the reagent, the Ultrasound Contrast agents segment is anticipated to dominate the global market owing to their increased application in multiple imaging methods. 

Preclinical In-vivo Imaging Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

Regionally, North America holds the largest share of the global preclinical imaging market, followed by Europe. North America dominates the global market given the rapid adoption by end-users of several types of modalities, technological advancement, and increased prevalence of chronic diseases like cancer, cardiovascular disease, and many others.

Factors including rising R&D activities by big pharma and biotech companies in developing nations and increased government funding for the pharmaceutical industry's development are stimulating the growth of the preclinical imaging market in the Asia-Pacific region.

KEY MARKET PLAYERS:

Companies like Aspect Imaging, Biospace Lab S.A., Bruker Corporation, LI-COR Biosciences, Mediso Ltd., MILabs B.V., MR Solutions Ltd, PerkinElmer, Inc., TriFoil Imaging, and FUJIFILM VisualSonics, Inc. are currently playing a leading role in the global preclinical in-vivo imaging market.

RECENT MARKET HAPPENINGS:

• Aspect Imaging, one of the market players in designing and developing compact magnetic resonance systems for preclinical, medical, and industrial applications, unveiled in September 2017 that Quantum Analytics will be its exclusive U.S. distributor for the Industrial product portfolio of Aspect Imaging.
• In mid-2019, Kawasaki Medical University, the research center for state-of-the-art medical science and services in Yokohama, acquired an ultra-high-resolution E-Class U-SPECT6/CT system for preclinical imaging and installed the first MILabs E-Class U-SPECT6/CT system in Japan.

THIS REPORT COMES WITH:

• Current and future Preclinical In-vivo Imaging Market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in excel)